Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health Co. demonstrated positive momentum in its 4Q23 performance, achieving revenue of $96.8 million, surpassing previous estimates of $95.2 million and $88.0 million due to strong performance in consumables. The company also reported a significant 20% quarterly increase in average selling price (ASP) for total systems, reaching $28.8K, which was notably higher than the prior estimate of $24.3K, attributed to a higher percentage of direct sales. Despite potential concerns regarding EBITDA guidance being back-end weighted, the overall revenue trajectory and improved ASP metrics suggest a robust foundation for future growth.

Bears say

Beauty Health has reported a significant decline in core delivery system placements, with new placements falling over 30% year-over-year and quarter-over-quarter, which raises concerns about the company's growth potential and future consumables sales. Furthermore, management's first-quarter 2024 sales guidance of $80 million and an adjusted EBITDA estimate of ($7.5 million) are notably below previous expectations, indicating potential challenges in meeting projected profitability targets. Additionally, there are substantial risks related to brand integrity, macroeconomic factors, competition, and execution of expansion initiatives, further contributing to a cautious outlook on the company’s financial health.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.